Yuhan Corp.
Yuhan Corporation manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods in South Korea and internationally. It also manufactures and sells animal feed and health functional food. The company was founded in 1926 and is headquartered in Seoul, South Korea.
Yuhan Corp. (000100) - Net Assets
Latest net assets as of September 2025: ₩2.22 Trillion KRW
Based on the latest financial reports, Yuhan Corp. (000100) has net assets worth ₩2.22 Trillion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩3.05 Trillion) and total liabilities (₩836.23 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩2.22 Trillion |
| % of Total Assets | 72.61% |
| Annual Growth Rate | 8.21% |
| 5-Year Change | 16.47% |
| 10-Year Change | 57.68% |
| Growth Volatility | 4.46 |
Yuhan Corp. - Net Assets Trend (2000–2024)
This chart illustrates how Yuhan Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Yuhan Corp. (2000–2024)
The table below shows the annual net assets of Yuhan Corp. from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩2.15 Trillion | +2.38% |
| 2023-12-31 | ₩2.10 Trillion | +4.62% |
| 2022-12-31 | ₩2.01 Trillion | +3.71% |
| 2021-12-31 | ₩1.94 Trillion | +4.84% |
| 2020-12-31 | ₩1.85 Trillion | +11.91% |
| 2019-12-31 | ₩1.65 Trillion | -0.11% |
| 2018-12-31 | ₩1.65 Trillion | +2.83% |
| 2017-12-31 | ₩1.61 Trillion | +7.34% |
| 2016-12-31 | ₩1.50 Trillion | +9.72% |
| 2015-12-31 | ₩1.36 Trillion | +6.90% |
| 2014-12-31 | ₩1.28 Trillion | +3.88% |
| 2013-12-31 | ₩1.23 Trillion | +3.37% |
| 2012-12-31 | ₩1.19 Trillion | +6.40% |
| 2011-12-31 | ₩1.12 Trillion | +4.10% |
| 2010-12-31 | ₩1.07 Trillion | +10.85% |
| 2009-12-31 | ₩967.71 Billion | +12.19% |
| 2008-12-31 | ₩862.60 Billion | +14.03% |
| 2007-12-31 | ₩756.45 Billion | +12.50% |
| 2006-12-31 | ₩672.40 Billion | +13.42% |
| 2005-12-31 | ₩592.86 Billion | +14.23% |
| 2004-12-31 | ₩519.03 Billion | +12.33% |
| 2003-12-31 | ₩462.04 Billion | +13.26% |
| 2002-12-31 | ₩407.93 Billion | +10.42% |
| 2001-12-31 | ₩369.44 Billion | +14.17% |
| 2000-12-31 | ₩323.58 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Yuhan Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 201002581639000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩2.01 Trillion | 95.69% |
| Other Components | ₩90.52 Billion | 4.31% |
| Total Equity | ₩2.10 Trillion | 100.00% |
Yuhan Corp. Competitors by Market Cap
The table below lists competitors of Yuhan Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bharat Heavy Electricals Limited
NSE:BHEL
|
$4.21 Billion |
|
Thyssenkrupp AG O.N.
PINK:TYEKF
|
$4.21 Billion |
|
Technip Energies N.V
PINK:THNPF
|
$4.21 Billion |
|
CALIWAY BIOPHARMACEUTICALS CO L
TW:6919
|
$4.21 Billion |
|
Vicinity Centres
PINK:CNRAF
|
$4.21 Billion |
|
Shenzhen Kaifa Technology Co Ltd
SHE:000021
|
$4.21 Billion |
|
Steadfast Group Ltd
PINK:SFGLF
|
$4.21 Billion |
|
Amundi SA
PINK:AMDUF
|
$4.20 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yuhan Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,051,255,050,440 to 2,100,543,104,230, a change of 49,288,053,790 (2.4%).
- Net income of 70,687,449,390 contributed positively to equity growth.
- Dividend payments of 32,145,147,300 reduced retained earnings.
- Share repurchases of 2,512,349,430 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩70.69 Billion | +3.37% |
| Dividends Paid | ₩32.15 Billion | -1.53% |
| Share Repurchases | ₩2.51 Billion | -0.12% |
| Other Changes | ₩13.26 Billion | +0.63% |
| Total Change | ₩- | 2.40% |
Book Value vs Market Value Analysis
This analysis compares Yuhan Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.50x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3.83x to 3.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩25980.93 | ₩99500.00 | x |
| 2018-12-31 | ₩26767.73 | ₩99500.00 | x |
| 2019-12-31 | ₩26904.01 | ₩99500.00 | x |
| 2020-12-31 | ₩30079.63 | ₩99500.00 | x |
| 2021-12-31 | ₩28584.38 | ₩99500.00 | x |
| 2022-12-31 | ₩28206.83 | ₩99500.00 | x |
| 2023-12-31 | ₩29195.29 | ₩99500.00 | x |
| 2024-12-31 | ₩28464.98 | ₩99500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yuhan Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.42%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.40x
- Recent ROE (3.37%) is below the historical average (8.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 10.19% | 14.75% | 0.40x | 1.72x | ₩617.79 Million |
| 2001 | 10.54% | 14.88% | 0.45x | 1.58x | ₩2.00 Billion |
| 2002 | 10.79% | 15.14% | 0.46x | 1.55x | ₩3.24 Billion |
| 2003 | 11.12% | 16.59% | 0.47x | 1.43x | ₩5.17 Billion |
| 2004 | 9.81% | 14.73% | 0.45x | 1.47x | ₩-996.98 Million |
| 2005 | 10.31% | 15.22% | 0.45x | 1.52x | ₩1.87 Billion |
| 2006 | 9.70% | 15.44% | 0.45x | 1.40x | ₩-2.01 Billion |
| 2007 | 11.87% | 18.20% | 0.49x | 1.32x | ₩14.12 Billion |
| 2008 | 14.22% | 20.07% | 0.59x | 1.20x | ₩36.38 Billion |
| 2009 | 12.29% | 18.39% | 0.57x | 1.17x | ₩22.20 Billion |
| 2010 | 11.67% | 18.87% | 0.53x | 1.17x | ₩17.92 Billion |
| 2011 | 8.27% | 13.60% | 0.52x | 1.18x | ₩-19.27 Billion |
| 2012 | 6.67% | 10.21% | 0.55x | 1.18x | ₩-39.57 Billion |
| 2013 | 6.91% | 8.99% | 0.62x | 1.23x | ₩-37.96 Billion |
| 2014 | 6.99% | 8.76% | 0.63x | 1.27x | ₩-38.47 Billion |
| 2015 | 9.25% | 11.17% | 0.60x | 1.38x | ₩-10.23 Billion |
| 2016 | 10.77% | 12.21% | 0.65x | 1.37x | ₩11.59 Billion |
| 2017 | 6.81% | 7.46% | 0.70x | 1.31x | ₩-50.96 Billion |
| 2018 | 3.50% | 3.78% | 0.70x | 1.32x | ₩-106.69 Billion |
| 2019 | 2.43% | 2.70% | 0.70x | 1.29x | ₩-124.62 Billion |
| 2020 | 10.48% | 11.90% | 0.68x | 1.30x | ₩8.75 Billion |
| 2021 | 5.32% | 6.08% | 0.69x | 1.28x | ₩-90.10 Billion |
| 2022 | 4.79% | 5.36% | 0.72x | 1.25x | ₩-103.44 Billion |
| 2023 | 6.64% | 7.33% | 0.66x | 1.37x | ₩-68.93 Billion |
| 2024 | 3.37% | 3.42% | 0.70x | 1.40x | ₩-139.37 Billion |
Industry Comparison
This section compares Yuhan Corp.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $170,228,056,156
- Average return on equity (ROE) among peers: 0.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yuhan Corp. (000100) | ₩2.22 Trillion | 10.19% | 0.38x | $4.21 Billion |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |